Sign in
Taking people in United StatesNo phase

Tests glucose sensors for people with diabetes after leaving hospital

Tests glucose sensor devices in adults with diabetes after hospital discharge.

Key facts

Who runs it
Vanderbilt University Medical Center
Where
Nashville, United StatesSee the site
Trial code
Registry title
Continuous Glucose Monitoring for Outpatient Diabetes Management After Hospital Discharge
Status
Recruiting
People taking part
60 people, planned
Started
9 Mar 2025
Expected to end
Jan 2027
Type of study
Interventional, 2 groups
Treatments tested
  • Libre 3 Plus Continuous Glucose Monitor
  • Dexcom G7 Continuous Glucose Monitor
Record updated
5 March 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults in hospital who need insulin for high blood sugar and will keep using it after discharge. It tests wearing a continuous glucose monitor after leaving hospital.

Age
18 years or older
Sex
All sexes can join
Disease stage
High blood sugar that needs insulin (injections or the person's own insulin pump) in hospital and at discharge. Recent glucose readings must be 70-350 mg/dL (3.9–19.4 mmol/L).
Earlier treatment
Must not have used a Libre 3 Plus or Dexcom G7 monitor in the past 3 months or during this hospital stay.

Main reasons for not taking part

  • Pregnant
  • Dialysis (hemodialysis or peritoneal)
  • Intensive care, intubation, sedation or vasopressors
  • Diabetic ketoacidosis or hyperosmotic nonketotic state
  • No smartphone that works with the Libre 3 or Dexcom G7 app

The registry criteria, word for word

Show all 18 criteriaShow less

Who can take part

  • Non-pregnant adults, ages greater than or equal to 18 years, admitted to VUMC
  • Able to give informed consent
  • Hyperglycemia requiring insulin therapy including subcutaneous insulin injection or continuous subcutaneous insulin infusion (patient's own insulin pump) during hospitalization and at the time of discharge
  • POC glucose or venous glucose levels in the 24 hours prior to participation need to be 70-350 mg/dL
  • Need glucose readings greater than or equal to one time per day
  • Mental status and dexterity adequate to use Libre 3 Plus or Dexcom G7 sensors with Libre 3 or Dexcom G7 application on patient's smartphone

Who cannot take part

  • Currently using Libre 3 Plus or Dexcom G7 CGMS during hospitalization or have used Libre 3 Plus or Dexcom G7 CGMS in the past 3 months
  • Received chemotherapy during current hospitalization
  • Planning on major surgery within 10-15 days
  • Significant pitting edema (3+ or greater) i.e. cirrhosis with ascites, congestive heart failure with edema, nephrotic syndrome, or signs of poor perfusion
  • Skin allergy to adhesives
  • Does not have smartphone compatible with Libre 3 App or Dexcom G7 App
  • Hemodialysis or peritoneal dialysis
  • Requiring vasopressors, intubation, sedation, or admission to an intensive care unit
  • Vitamin C use of more than 500 milligrams per day
  • Hydroxyurea use
  • Acetaminophen use of more than 4 grams per day or 1 gram every 6 hours
  • Presentation in diabetic ketoacidosis or hyperosmotic nonketotic state

Where in United States

  • Vanderbilt University Medical CenterNashville, United StatesContact: Angel Morvant, MDTaking people

About the trial

What the trial wants to find out

This study aims to improve patient awareness of the utility of continuous glucose monitoring systems in blood glucose monitoring and to improve patient satisfaction regarding diabetes care, particularly in the matter of blood glucose monitoring, at the transitions of care from the inpatient setting to the ambulatory setting.

The 2 groups in the trial

  • Libre 3 Plus Continuous Glucose MonitorTreatment being tested

    Subjects in this arm will start using the Libre 3 Plus continuous glucose monitor.

  • Dexcom G7 Continuous Glucose MonitorTreatment being tested

    Subjects in this arm will start using the Dexcom G7 continuous glucose monitor.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Continuous Glucose Monitoring for Outpatient Diabetes Management After Hospital Discharge
Plain-language title
Tests glucose sensors for people with diabetes after leaving hospitalGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
5 March 2026